Patient Characteristics in Relation to 18F-FDG Uptake in Primary Tumors (n = 291)
| Characteristic | Value | TLR (mean ± SD) | P |
| Age (y) | 57.1 ± 10.5 (range, 29–84) | 0.72 | |
| <57 vs. ≥57 | 4.0 ± 1.9 vs. 3.9 ± 2.3 | ||
| Sex (n) | 0.14 | ||
| Male | 251 (86.3) | 3.8 ± 2.1 | |
| Female | 40 (13.7) | 4.4 ± 2.2 | |
| Etiology of hepatitis (n) | 0.52 | ||
| HBV | 225 (77.3) | 4.0 ± 2.0 | |
| HCV | 20 (6.9) | 3.5 ± 1.9 | |
| Alcoholic | 20 (6.9) | 3.7 ± 2.9 | |
| Unknown | 26 (8.9) | 3.8 ± 2.1 | |
| Child–Pugh classification (n) | 0.69 | ||
| A | 233 (80.0) | 3.9 ± 2.1 | |
| B | 58 (20.0) | 3.8 ± 1.9 | |
| Tumor size on CT or MRI (cm) | 10.3 ± 4.1 (range, 3.1–21.1) | 0.09 | |
| <10.3 vs. ≥10.3 | 3.7 ± 2.2 vs. 4.1 ± 2.0 | ||
| Tumor number (n) | 0.64 | ||
| <4 | 123 (42.4) | 3.8 ± 2.0 | |
| ≥4 | 161 (57.6) | 4.0 ± 2.1 | |
| AFP (ng/mL) | Median, 1,466 (range, 1.0–3,500,000) | 0.54 | |
| <1,466 vs. ≥1,466 | 3.9 ± 2.3 vs. 4.0 ± 1.8 | ||
| PIVKA-II (mAU/mL) | Median, 1,200 (range, 6–20,000) | 0.78 | |
| <1,200 vs. ≥1,200 | 4.0 ± 2.3 vs 3.9 ± 2.0 | ||
| Disease extent (n) | 0.018 | ||
| Intrahepatic | 153 (52.6) | 3.6 ± 2.0 | |
| Extrahepatic | 138 (47.4) | 4.2 ± 2.2 | |
| Portal vein invasion | 0.84 | ||
| Absence | 55 (18.9) | 3.9 ± 1.9 | |
| Presence | 236 (81.1) | 3.9 ± 2.1 | |
| Treatment (n) | 0.61 | ||
| Local therapy | 232 (79.7) | 3.9 ± 2.2 | |
| Systemic therapy | 59 (20.3) | 4.0 ± 1.7 |
HBV = hepatitis B virus; HCV = hepatitis C virus.
Data are mean ± SD or n, and data in parentheses are percentages unless otherwise marked.